Nuvation Bio Inc. 8-K

What Happened

• Nuvation Bio Inc. (NASDAQ: NUVB) filed a Form 8-K on May 4, 2026 announcing it issued a press release with its financial results for the quarter ended March 31, 2026. The press release is furnished as Exhibit 99.1 to the Form 8-K. The 8-K notes that the information in the press release is furnished (not “filed”) for purposes of Section 18 of the Securities Exchange Act.

Key Details

• Filing date: May 4, 2026.
• Reporting period: quarter ended March 31, 2026.
• Exhibit: Press release furnished as Exhibit 99.1 to the Form 8-K.
• Disclosure status: Information in the press release is furnished and therefore not deemed “filed” or automatically incorporated by reference into other SEC filings.

Why It Matters

• Quarterly financial results provide updated metrics investors use to evaluate company performance (earnings, revenue, cash position, R&D spending, etc.). Because Nuvation Bio furnished a press release with its Q1 2026 results, investors should review Exhibit 99.1 for the detailed numbers and any operational updates, and watch for subsequent SEC filings (such as the quarterly report on Form 10-Q) for the official, filed financial statements.